Is Regeneron Pharmaceuticals Due for a Stock Split?
Regeneron Pharmaceuticals (NASDAQ: REGN) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price, making it more accessible to investors who can't buy fractional shares, or who simply don't want to do so. It would also give the stock some great, positive free press, which could potentially lead to even more of a rally.
Should investors expect Regeneron's stock to split in the near future? Here's a look at whether it may happen, and what it would mean for investors if Regeneron does enact a stock split.
Since Regeneron went public in 1991, the healthcare stock has never split its shares. It would be a great milestone for the company, not because it would mean the business is somehow better, but because it would underscore the growth it has achieved over the years. For a stock to rise as highly in value as Regeneron has, the company would have to be generating some strong results.
Source Fool.com
Regeneron Pharmaceuticals Inc. Aktie
Klares Buy-Übergewicht bei der Regeneron Pharmaceuticals Inc. Aktie mit 54 zu 2 Einschätzungen.
Für Regeneron Pharmaceuticals Inc. liegt das Community-Kursziel bei 1037 €, was eine erhebliche Steigerung gegenüber dem aktuellen Kurs von 470.1 € darstellt.
